JP2011507861A

JP2011507861A - 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用

線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用 Download PDF

Info

Publication number: JP2011507861A
Authority: JP; Japan
Prior art keywords: connexin; peptide; polynucleotide; fibrosis; composition
Prior art date: 2007-12-21
Legal status : Withdrawn

Application number

JP2010539518A

Other languages

English (en)

Japanese (ja)

Other versions

JP2011507861A5 (enExample

Inventor

ブラッドフォードジェイ．ダフト，

Original Assignee

コーダセラピューティクス，インコーポレイテッド

Priority date

2007-12-21

Filing date

2008-12-22

Publication date

2011-03-10

2008-12-22 Application filed by コーダセラピューティクス，インコーポレイテッド filed Critical コーダセラピューティクス，インコーポレイテッド

2011-03-10 Publication of JP2011507861A publication Critical patent/JP2011507861A/ja

2013-04-25 Publication of JP2011507861A5 publication Critical patent/JP2011507861A5/ja

Status Withdrawn legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 367
108091033319 polynucleotide Proteins 0.000 title claims abstract description 264
102000040430 polynucleotide Human genes 0.000 title claims abstract description 264
239000002157 polynucleotide Substances 0.000 title claims abstract description 264
230000003176 fibrotic effect Effects 0.000 title claims abstract description 199
239000003795 chemical substances by application Substances 0.000 title claims description 330
238000011282 treatment Methods 0.000 title claims description 75
102000004196 processed proteins & peptides Human genes 0.000 title abstract description 225
229920001184 polypeptide Polymers 0.000 title description 72
108050001175 Connexin Proteins 0.000 claims abstract description 401
102000010970 Connexin Human genes 0.000 claims abstract description 397
239000000203 mixture Substances 0.000 claims abstract description 255
210000003976 gap junction Anatomy 0.000 claims abstract description 220
239000000816 peptidomimetic Substances 0.000 claims abstract description 176
206010016654 Fibrosis Diseases 0.000 claims abstract description 160
230000004761 fibrosis Effects 0.000 claims abstract description 155
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 151
238000000034 method Methods 0.000 claims abstract description 149
201000010099 disease Diseases 0.000 claims abstract description 76
208000035475 disorder Diseases 0.000 claims abstract description 75
239000003607 modifier Substances 0.000 claims abstract description 73
239000003814 drug Substances 0.000 claims description 69
230000000692 anti-sense effect Effects 0.000 claims description 62
150000001875 compounds Chemical class 0.000 claims description 62
239000008194 pharmaceutical composition Substances 0.000 claims description 61
108010069241 Connexin 43 Proteins 0.000 claims description 54
102000001045 Connexin 43 Human genes 0.000 claims description 54
108020004999 messenger RNA Proteins 0.000 claims description 38
230000014509 gene expression Effects 0.000 claims description 32
241001465754 Metazoa Species 0.000 claims description 24
108091034117 Oligonucleotide Proteins 0.000 claims description 21
239000002773 nucleotide Substances 0.000 claims description 19
125000003729 nucleotide group Chemical group 0.000 claims description 19
241000124008 Mammalia Species 0.000 claims description 15
230000002265 prevention Effects 0.000 claims description 11
229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 9
108020004459 Small interfering RNA Proteins 0.000 claims description 9
230000000295 complement effect Effects 0.000 claims description 9
108091030071 RNAI Proteins 0.000 claims description 8
229920001983 poloxamer Polymers 0.000 claims description 8
239000001768 carboxy methyl cellulose Substances 0.000 claims description 7
235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 7
239000008112 carboxymethyl-cellulose Substances 0.000 claims description 7
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
238000011200 topical administration Methods 0.000 claims description 5
230000003510 anti-fibrotic effect Effects 0.000 claims description 4
238000002844 melting Methods 0.000 claims description 4
230000008018 melting Effects 0.000 claims description 4
230000004962 physiological condition Effects 0.000 claims description 4
229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 4
239000005022 packaging material Substances 0.000 claims description 3
101800005309 Carboxy-terminal peptide Proteins 0.000 claims 2
244000144972 livestock Species 0.000 claims 2
230000006916 protein interaction Effects 0.000 claims 2
208000027418 Wounds and injury Diseases 0.000 description 90
206010052428 Wound Diseases 0.000 description 79
238000009472 formulation Methods 0.000 description 72
229940079593 drug Drugs 0.000 description 55
150000001413 amino acids Chemical class 0.000 description 50
210000001519 tissue Anatomy 0.000 description 49
230000000694 effects Effects 0.000 description 44
210000004027 cell Anatomy 0.000 description 39
239000000499 gel Substances 0.000 description 36
125000003275 alpha amino acid group Chemical group 0.000 description 35
239000010408 film Substances 0.000 description 34
230000027455 binding Effects 0.000 description 29
238000009739 binding Methods 0.000 description 29
208000006111 contracture Diseases 0.000 description 29
230000006870 function Effects 0.000 description 26
230000029663 wound healing Effects 0.000 description 25
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 24
230000000865 phosphorylative effect Effects 0.000 description 24
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 23
239000002953 phosphate buffered saline Substances 0.000 description 23
239000000463 material Substances 0.000 description 22
230000015572 biosynthetic process Effects 0.000 description 21
208000014674 injury Diseases 0.000 description 21
230000037396 body weight Effects 0.000 description 20
229940046166 oligodeoxynucleotide Drugs 0.000 description 20
206010062575 Muscle contracture Diseases 0.000 description 19
239000011159 matrix material Substances 0.000 description 19
-1 for example Proteins 0.000 description 18
108090000623 proteins and genes Proteins 0.000 description 18
210000001723 extracellular space Anatomy 0.000 description 17
238000002360 preparation method Methods 0.000 description 17
235000018102 proteins Nutrition 0.000 description 17
102000004169 proteins and genes Human genes 0.000 description 17
239000000853 adhesive Substances 0.000 description 16
239000012634 fragment Substances 0.000 description 16
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 16
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 16
102000016359 Fibronectins Human genes 0.000 description 15
108010067306 Fibronectins Proteins 0.000 description 15
208000019425 cirrhosis of liver Diseases 0.000 description 15
239000000047 product Substances 0.000 description 15
239000000243 solution Substances 0.000 description 15
102000014914 Carrier Proteins Human genes 0.000 description 14
108091008324 binding proteins Proteins 0.000 description 14
239000003112 inhibitor Substances 0.000 description 14
230000026731 phosphorylation Effects 0.000 description 14
238000006366 phosphorylation reaction Methods 0.000 description 14
239000007787 solid Substances 0.000 description 14
238000012360 testing method Methods 0.000 description 14
230000001154 acute effect Effects 0.000 description 13
230000000996 additive effect Effects 0.000 description 13
230000001070 adhesive effect Effects 0.000 description 13
239000000017 hydrogel Substances 0.000 description 13
239000010410 layer Substances 0.000 description 13
208000005069 pulmonary fibrosis Diseases 0.000 description 13
238000006467 substitution reaction Methods 0.000 description 13
230000000699 topical effect Effects 0.000 description 13
235000021323 fish oil Nutrition 0.000 description 12
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 12
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 12
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 12
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 12
230000009467 reduction Effects 0.000 description 12
102000008186 Collagen Human genes 0.000 description 11
108010035532 Collagen Proteins 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
229920001436 collagen Polymers 0.000 description 11
230000006378 damage Effects 0.000 description 11
239000002552 dosage form Substances 0.000 description 11
210000003734 kidney Anatomy 0.000 description 11
230000008569 process Effects 0.000 description 11
230000002195 synergetic effect Effects 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 10
210000000805 cytoplasm Anatomy 0.000 description 10
239000003937 drug carrier Substances 0.000 description 10
239000006260 foam Substances 0.000 description 10
230000001225 therapeutic effect Effects 0.000 description 10
102100039290 Gap junction gamma-1 protein Human genes 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
238000009825 accumulation Methods 0.000 description 9
230000001684 chronic effect Effects 0.000 description 9
108010015426 connexin 45 Proteins 0.000 description 9
230000005764 inhibitory process Effects 0.000 description 9
238000004519 manufacturing process Methods 0.000 description 9
208000011580 syndromic disease Diseases 0.000 description 9
102000012422 Collagen Type I Human genes 0.000 description 8
108010022452 Collagen Type I Proteins 0.000 description 8
101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 8
102000008394 Immunoglobulin Fragments Human genes 0.000 description 8
108010021625 Immunoglobulin Fragments Proteins 0.000 description 8
206010028594 Myocardial fibrosis Diseases 0.000 description 8
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 8
230000002159 abnormal effect Effects 0.000 description 8
238000002648 combination therapy Methods 0.000 description 8
230000003828 downregulation Effects 0.000 description 8
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 8
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 8
229960002216 methylparaben Drugs 0.000 description 8
239000002674 ointment Substances 0.000 description 8
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 8
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 8
229960003415 propylparaben Drugs 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
230000008733 trauma Effects 0.000 description 8
206010061218 Inflammation Diseases 0.000 description 7
239000002250 absorbent Substances 0.000 description 7
230000002745 absorbent Effects 0.000 description 7
235000010443 alginic acid Nutrition 0.000 description 7
229920000615 alginic acid Polymers 0.000 description 7
239000006071 cream Substances 0.000 description 7
206010061989 glomerulosclerosis Diseases 0.000 description 7
230000004054 inflammatory process Effects 0.000 description 7
230000035992 intercellular communication Effects 0.000 description 7
239000008363 phosphate buffer Substances 0.000 description 7
230000005855 radiation Effects 0.000 description 7
231100000241 scar Toxicity 0.000 description 7
150000003384 small molecules Chemical class 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 6
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 6
108060003393 Granulin Proteins 0.000 description 6
208000000185 Localized scleroderma Diseases 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
241000700159 Rattus Species 0.000 description 6
239000000654 additive Substances 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
238000004422 calculation algorithm Methods 0.000 description 6
239000000969 carrier Substances 0.000 description 6
238000002512 chemotherapy Methods 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
239000000839 emulsion Substances 0.000 description 6
210000002744 extracellular matrix Anatomy 0.000 description 6
238000000605 extraction Methods 0.000 description 6
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 6
230000003993 interaction Effects 0.000 description 6
210000004185 liver Anatomy 0.000 description 6
238000005259 measurement Methods 0.000 description 6
210000003205 muscle Anatomy 0.000 description 6
210000001322 periplasm Anatomy 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
230000000750 progressive effect Effects 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
239000000126 substance Substances 0.000 description 6
238000013268 sustained release Methods 0.000 description 6
239000012730 sustained-release form Substances 0.000 description 6
238000013519 translation Methods 0.000 description 6
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 5
208000001708 Dupuytren contracture Diseases 0.000 description 5
208000014919 IgG4-related retroperitoneal fibrosis Diseases 0.000 description 5
206010028980 Neoplasm Diseases 0.000 description 5
206010038979 Retroperitoneal fibrosis Diseases 0.000 description 5
206010039710 Scleroderma Diseases 0.000 description 5
229920002385 Sodium hyaluronate Polymers 0.000 description 5
229940072056 alginate Drugs 0.000 description 5
125000000539 amino acid group Chemical group 0.000 description 5
230000000903 blocking effect Effects 0.000 description 5
229910052799 carbon Inorganic materials 0.000 description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
230000007882 cirrhosis Effects 0.000 description 5
239000002131 composite material Substances 0.000 description 5
239000003405 delayed action preparation Substances 0.000 description 5
230000003111 delayed effect Effects 0.000 description 5
239000003995 emulsifying agent Substances 0.000 description 5
239000000945 filler Substances 0.000 description 5
208000005017 glioblastoma Diseases 0.000 description 5
238000001802 infusion Methods 0.000 description 5
230000000670 limiting effect Effects 0.000 description 5
239000007788 liquid Substances 0.000 description 5
210000004379 membrane Anatomy 0.000 description 5
239000012528 membrane Substances 0.000 description 5
206010028537 myelofibrosis Diseases 0.000 description 5
239000012188 paraffin wax Substances 0.000 description 5
229920001610 polycaprolactone Polymers 0.000 description 5
239000000843 powder Substances 0.000 description 5
201000002793 renal fibrosis Diseases 0.000 description 5
230000004044 response Effects 0.000 description 5
230000011664 signaling Effects 0.000 description 5
229940010747 sodium hyaluronate Drugs 0.000 description 5
YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 5
239000000758 substrate Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
239000010409 thin film Substances 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
239000003981 vehicle Substances 0.000 description 5
MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 4
102000007469 Actins Human genes 0.000 description 4
108010085238 Actins Proteins 0.000 description 4
208000033116 Asbestos intoxication Diseases 0.000 description 4
241000271566 Aves Species 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
108010069156 Connexin 26 Proteins 0.000 description 4
208000007342 Diabetic Nephropathies Diseases 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
102100030540 Gap junction alpha-5 protein Human genes 0.000 description 4
102100037156 Gap junction beta-2 protein Human genes 0.000 description 4
102100039417 Gap junction beta-5 protein Human genes 0.000 description 4
206010018364 Glomerulonephritis Diseases 0.000 description 4
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 4
102000004877 Insulin Human genes 0.000 description 4
108090001061 Insulin Proteins 0.000 description 4
208000001055 Ischemic Contracture Diseases 0.000 description 4
MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 description 4
KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 4
239000012980 RPMI-1640 medium Substances 0.000 description 4
201000010001 Silicosis Diseases 0.000 description 4
201000000027 Volkmann contracture Diseases 0.000 description 4
230000001494 anti-thymocyte effect Effects 0.000 description 4
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
206010003441 asbestosis Diseases 0.000 description 4
230000004888 barrier function Effects 0.000 description 4
239000012620 biological material Substances 0.000 description 4
230000001851 biosynthetic effect Effects 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
230000001413 cellular effect Effects 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
235000010980 cellulose Nutrition 0.000 description 4
238000011284 combination treatment Methods 0.000 description 4
108010021208 connexin 31.1 Proteins 0.000 description 4
108010014510 connexin 40 Proteins 0.000 description 4
208000033679 diabetic kidney disease Diseases 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
239000008387 emulsifying waxe Substances 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
210000000416 exudates and transudate Anatomy 0.000 description 4
239000000835 fiber Substances 0.000 description 4
239000002657 fibrous material Substances 0.000 description 4
LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 4
230000005714 functional activity Effects 0.000 description 4
210000002216 heart Anatomy 0.000 description 4
239000000416 hydrocolloid Substances 0.000 description 4
238000003125 immunofluorescent labeling Methods 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
229940125396 insulin Drugs 0.000 description 4
208000036971 interstitial lung disease 2 Diseases 0.000 description 4
208000017169 kidney disease Diseases 0.000 description 4
210000005265 lung cell Anatomy 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
238000012261 overproduction Methods 0.000 description 4
208000030346 palmar fibromatosis Diseases 0.000 description 4
230000036961 partial effect Effects 0.000 description 4
230000007170 pathology Effects 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
229920003023 plastic Polymers 0.000 description 4
239000004033 plastic Substances 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
238000007619 statistical method Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
230000002459 sustained effect Effects 0.000 description 4
230000008685 targeting Effects 0.000 description 4
208000031261 Acute myeloid leukaemia Diseases 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
108010069176 Connexin 30 Proteins 0.000 description 3
229920000742 Cotton Polymers 0.000 description 3
208000011231 Crohn disease Diseases 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
206010014954 Eosinophilic fasciitis Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
102100030525 Gap junction alpha-4 protein Human genes 0.000 description 3
102100039401 Gap junction beta-6 protein Human genes 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
208000022559 Inflammatory bowel disease Diseases 0.000 description 3
208000029523 Interstitial Lung disease Diseases 0.000 description 3
208000007766 Kaposi sarcoma Diseases 0.000 description 3
206010024229 Leprosy Diseases 0.000 description 3
208000019693 Lung disease Diseases 0.000 description 3
206010027982 Morphoea Diseases 0.000 description 3
201000003793 Myelodysplastic syndrome Diseases 0.000 description 3
101710163270 Nuclease Proteins 0.000 description 3
206010033645 Pancreatitis Diseases 0.000 description 3
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 3
101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 3
229920000297 Rayon Polymers 0.000 description 3
239000004809 Teflon Substances 0.000 description 3
229920006362 Teflon® Polymers 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
230000002300 anti-fibrosis Effects 0.000 description 3
239000000074 antisense oligonucleotide Substances 0.000 description 3
238000012230 antisense oligonucleotides Methods 0.000 description 3
230000033228 biological regulation Effects 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
230000009787 cardiac fibrosis Effects 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
229960000541 cetyl alcohol Drugs 0.000 description 3
230000007881 chronic fibrosis Effects 0.000 description 3
208000020832 chronic kidney disease Diseases 0.000 description 3
208000022831 chronic renal failure syndrome Diseases 0.000 description 3
108010015408 connexin 37 Proteins 0.000 description 3
230000001276 controlling effect Effects 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
230000001186 cumulative effect Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
235000014113 dietary fatty acids Nutrition 0.000 description 3
230000002222 downregulating effect Effects 0.000 description 3
229960003720 enoxolone Drugs 0.000 description 3
239000005038 ethylene vinyl acetate Substances 0.000 description 3
239000000194 fatty acid Substances 0.000 description 3
229930195729 fatty acid Natural products 0.000 description 3
150000004665 fatty acids Chemical class 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
230000009368 gene silencing by RNA Effects 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
230000001976 improved effect Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000003446 ligand Substances 0.000 description 3
208000016809 linear scleroderma Diseases 0.000 description 3
239000006210 lotion Substances 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
210000000214 mouth Anatomy 0.000 description 3
208000025113 myeloid leukemia Diseases 0.000 description 3
206010065988 nodular fasciitis Diseases 0.000 description 3
102000039446 nucleic acids Human genes 0.000 description 3
108020004707 nucleic acids Proteins 0.000 description 3
150000007523 nucleic acids Chemical class 0.000 description 3
239000003921 oil Substances 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000003204 osmotic effect Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 3
201000006081 pseudosarcomatous fibromatosis Diseases 0.000 description 3
239000002964 rayon Substances 0.000 description 3
239000007790 solid phase Substances 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000008961 swelling Effects 0.000 description 3
208000024891 symptom Diseases 0.000 description 3
208000037999 tubulointerstitial fibrosis Diseases 0.000 description 3
150000003721 vitamin K derivatives Chemical class 0.000 description 3
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
VAZJLPXFVQHDFB-UHFFFAOYSA-N 1-(diaminomethylidene)-2-hexylguanidine Polymers CCCCCCN=C(N)N=C(N)N VAZJLPXFVQHDFB-UHFFFAOYSA-N 0.000 description 2
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
BBMCTIGTTCKYKF-UHFFFAOYSA-N 1-heptanol Chemical compound CCCCCCCO BBMCTIGTTCKYKF-UHFFFAOYSA-N 0.000 description 2
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
FAJKLRGSIQZGIB-UHFFFAOYSA-N 4-chloro-3-hydroxy-3h-furan-2-one Chemical compound OC1C(=O)OC=C1Cl FAJKLRGSIQZGIB-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
208000012260 Accidental injury Diseases 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
102000029330 CSK Tyrosine-Protein Kinase Human genes 0.000 description 2
108010069682 CSK Tyrosine-Protein Kinase Proteins 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
102000001187 Collagen Type III Human genes 0.000 description 2
108010069502 Collagen Type III Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
206010014664 Endocardial fibrosis Diseases 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
206010015124 Ergot poisoning Diseases 0.000 description 2
229940080349 GPR agonist Drugs 0.000 description 2
102100037260 Gap junction beta-1 protein Human genes 0.000 description 2
MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 2
239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 2
206010048654 Muscle fibrosis Diseases 0.000 description 2
PHSRRHGYXQCRPU-AWEZNQCLSA-N N-(3-oxododecanoyl)-L-homoserine lactone Chemical compound CCCCCCCCCC(=O)CC(=O)N[C@H]1CCOC1=O PHSRRHGYXQCRPU-AWEZNQCLSA-N 0.000 description 2
JZFPYUNJRRFVQU-UHFFFAOYSA-N Niflumic acid Chemical compound OC(=O)C1=CC=CN=C1NC1=CC=CC(C(F)(F)F)=C1 JZFPYUNJRRFVQU-UHFFFAOYSA-N 0.000 description 2
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
108010009711 Phalloidine Proteins 0.000 description 2
108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
108010077971 Plasminogen Inactivators Proteins 0.000 description 2
102000010752 Plasminogen Inactivators Human genes 0.000 description 2
229920002413 Polyhexanide Polymers 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
241000282887 Suidae Species 0.000 description 2
NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
102000007000 Tenascin Human genes 0.000 description 2
108010008125 Tenascin Proteins 0.000 description 2
102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
102000009618 Transforming Growth Factors Human genes 0.000 description 2
108010009583 Transforming Growth Factors Proteins 0.000 description 2
101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
230000002788 anti-peptide Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
229940114079 arachidonic acid Drugs 0.000 description 2
235000021342 arachidonic acid Nutrition 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000005540 biological transmission Effects 0.000 description 2
210000000988 bone and bone Anatomy 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000008568 cell cell communication Effects 0.000 description 2
230000006727 cell loss Effects 0.000 description 2
230000005754 cellular signaling Effects 0.000 description 2
229940082500 cetostearyl alcohol Drugs 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
238000004140 cleaning Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
229940096422 collagen type i Drugs 0.000 description 2
210000002808 connective tissue Anatomy 0.000 description 2
108010015416 connexin 32 Proteins 0.000 description 2
239000003246 corticosteroid Substances 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
230000002354 daily effect Effects 0.000 description 2
230000034994 death Effects 0.000 description 2
230000001804 emulsifying effect Effects 0.000 description 2
238000005538 encapsulation Methods 0.000 description 2
210000001174 endocardium Anatomy 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000004744 fabric Substances 0.000 description 2
229960004369 flufenamic acid Drugs 0.000 description 2
239000012530 fluid Substances 0.000 description 2
108010044046 gap 27 peptide Proteins 0.000 description 2
239000011521 glass Substances 0.000 description 2
150000004676 glycans Chemical class 0.000 description 2
230000035876 healing Effects 0.000 description 2
230000036732 histological change Effects 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
238000002169 hydrotherapy Methods 0.000 description 2
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
238000010191 image analysis Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000007972 injectable composition Substances 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000005342 ion exchange Methods 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
229960003803 meclofenamic acid Drugs 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
208000030159 metabolic disease Diseases 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical class CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
238000003032 molecular docking Methods 0.000 description 2
238000010172 mouse model Methods 0.000 description 2
230000004118 muscle contraction Effects 0.000 description 2
230000035772 mutation Effects 0.000 description 2
230000002071 myeloproliferative effect Effects 0.000 description 2
229960000916 niflumic acid Drugs 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
239000012454 non-polar solvent Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
230000037311 normal skin Effects 0.000 description 2
229920001778 nylon Polymers 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
239000003973 paint Substances 0.000 description 2
230000035515 penetration Effects 0.000 description 2
KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
238000002823 phage display Methods 0.000 description 2
239000002797 plasminogen activator inhibitor Substances 0.000 description 2
229920001993 poloxamer 188 Polymers 0.000 description 2
229940044519 poloxamer 188 Drugs 0.000 description 2
239000004632 polycaprolactone Substances 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
229920001282 polysaccharide Polymers 0.000 description 2
239000005017 polysaccharide Substances 0.000 description 2
229920001296 polysiloxane Polymers 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
230000002335 preservative effect Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
238000001959 radiotherapy Methods 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
239000012925 reference material Substances 0.000 description 2
230000002787 reinforcement Effects 0.000 description 2
108091092562 ribozyme Proteins 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
230000036573 scar formation Effects 0.000 description 2
239000001509 sodium citrate Substances 0.000 description 2
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000004611 spectroscopical analysis Methods 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
210000004500 stellate cell Anatomy 0.000 description 2
125000001424 substituent group Chemical group 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 2
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
239000012049 topical pharmaceutical composition Substances 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000003151 transfection method Methods 0.000 description 2
229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
235000012431 wafers Nutrition 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 description 1
OPCHFPHZPIURNA-MFERNQICSA-N (2s)-2,5-bis(3-aminopropylamino)-n-[2-(dioctadecylamino)acetyl]pentanamide Chemical compound CCCCCCCCCCCCCCCCCCN(CC(=O)NC(=O)[C@H](CCCNCCCN)NCCCN)CCCCCCCCCCCCCCCCCC OPCHFPHZPIURNA-MFERNQICSA-N 0.000 description 1
ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 description 1
PZVRZRARFZZBCA-SOFGYWHQSA-N 2',5'-Dihydroxychalcone Chemical compound OC1=CC=C(O)C(C(=O)\C=C\C=2C=CC=CC=2)=C1 PZVRZRARFZZBCA-SOFGYWHQSA-N 0.000 description 1
BSWWXRFVMJHFBN-UHFFFAOYSA-N 2,4,6-tribromophenol Chemical compound OC1=C(Br)C=C(Br)C=C1Br BSWWXRFVMJHFBN-UHFFFAOYSA-N 0.000 description 1
SNBCLPGEMZEWLU-QXFUBDJGSA-N 2-chloro-n-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl]acetamide Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CNC(=O)CCl)[C@@H](O)C1 SNBCLPGEMZEWLU-QXFUBDJGSA-N 0.000 description 1
WDEQLMYIIXBHTJ-UHFFFAOYSA-N 4-chloro-3-(chloromethyl)-2-hydroxy-2h-furan-5-one Chemical compound OC1OC(=O)C(Cl)=C1CCl WDEQLMYIIXBHTJ-UHFFFAOYSA-N 0.000 description 1
HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
108091027075 5S-rRNA precursor Proteins 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
235000001674 Agaricus brunnescens Nutrition 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
241000948470 Amanita phalloides Species 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010056375 Bile duct obstruction Diseases 0.000 description 1
241001474374 Blennius Species 0.000 description 1
QCMYYKRYFNMIEC-UHFFFAOYSA-N COP(O)=O Chemical class COP(O)=O QCMYYKRYFNMIEC-UHFFFAOYSA-N 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 description 1
206010008635 Cholestasis Diseases 0.000 description 1
235000001258 Cinchona calisaya Nutrition 0.000 description 1
GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
206010012335 Dependence Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
102100039397 Gap junction beta-3 protein Human genes 0.000 description 1
101710082451 Gap junction beta-3 protein Proteins 0.000 description 1
102100039416 Gap junction beta-4 protein Human genes 0.000 description 1
102100025623 Gap junction delta-2 protein Human genes 0.000 description 1
101710129297 Gap junction delta-4 protein Proteins 0.000 description 1
102100025627 Gap junction delta-4 protein Human genes 0.000 description 1
102100039288 Gap junction gamma-2 protein Human genes 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000018565 Hemochromatosis Diseases 0.000 description 1
206010019663 Hepatic failure Diseases 0.000 description 1
206010019799 Hepatitis viral Diseases 0.000 description 1
208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
108010068250 Herpes Simplex Virus Protein Vmw65 Proteins 0.000 description 1
101000746084 Homo sapiens Gap junction gamma-2 protein Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
102000008070 Interferon-gamma Human genes 0.000 description 1
108010074328 Interferon-gamma Proteins 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
239000004166 Lanolin Substances 0.000 description 1
102000003820 Lipoxygenases Human genes 0.000 description 1
108090000128 Lipoxygenases Proteins 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
238000000585 Mann–Whitney U test Methods 0.000 description 1
206010027476 Metastases Diseases 0.000 description 1
206010027727 Mitral valve incompetence Diseases 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
208000021642 Muscular disease Diseases 0.000 description 1
208000031888 Mycoses Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
XJGBDJOMWKAZJS-UHFFFAOYSA-N Nafenoic Acid Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C2=CC=CC=C2CCC1 XJGBDJOMWKAZJS-UHFFFAOYSA-N 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
206010031023 Oral submucosal fibrosis Diseases 0.000 description 1
206010053159 Organ failure Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001494479 Pecora Species 0.000 description 1
208000004362 Penile Induration Diseases 0.000 description 1
239000004264 Petrolatum Substances 0.000 description 1
208000020758 Peyronie disease Diseases 0.000 description 1
229920002873 Polyethylenimine Polymers 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920000289 Polyquaternium Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
206010038748 Restrictive cardiomyopathy Diseases 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
201000009594 Systemic Scleroderma Diseases 0.000 description 1
206010042953 Systemic sclerosis Diseases 0.000 description 1
IUJDSEJGGMCXSG-UHFFFAOYSA-N Thiopental Chemical compound CCCC(C)C1(CC)C(=O)NC(=S)NC1=O IUJDSEJGGMCXSG-UHFFFAOYSA-N 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
206010043994 Tonic convulsion Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
206010052779 Transplant rejections Diseases 0.000 description 1
201000001943 Tricuspid Valve Insufficiency Diseases 0.000 description 1
206010044640 Tricuspid valve incompetence Diseases 0.000 description 1
241000209140 Triticum Species 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
229930003448 Vitamin K Natural products 0.000 description 1
208000018839 Wilson disease Diseases 0.000 description 1
241000269370 Xenopus <genus> Species 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
239000002535 acidifier Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012790 adhesive layer Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
230000033115 angiogenesis Effects 0.000 description 1
239000003957 anion exchange resin Substances 0.000 description 1
PYKYMHQGRFAEBM-UHFFFAOYSA-N anthraquinone Natural products CCC(=O)c1c(O)c2C(=O)C3C(C=CC=C3O)C(=O)c2cc1CC(=O)OC PYKYMHQGRFAEBM-UHFFFAOYSA-N 0.000 description 1
150000004056 anthraquinones Chemical class 0.000 description 1
230000002924 anti-infective effect Effects 0.000 description 1
230000000845 anti-microbial effect Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000001130 astrocyte Anatomy 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
CREXVNNSNOKDHW-UHFFFAOYSA-N azaniumylideneazanide Chemical group N[N] CREXVNNSNOKDHW-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000011324 bead Substances 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000012867 bioactive agent Substances 0.000 description 1
230000003851 biochemical process Effects 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
210000005068 bladder tissue Anatomy 0.000 description 1
201000000053 blastoma Diseases 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
210000005178 buccal mucosa Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
239000004202 carbamide Substances 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
238000005266 casting Methods 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
230000020411 cell activation Effects 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
230000005779 cell damage Effects 0.000 description 1
210000002390 cell membrane structure Anatomy 0.000 description 1
239000007765 cera alba Substances 0.000 description 1
239000007766 cera flava Substances 0.000 description 1
235000005513 chalcones Nutrition 0.000 description 1
238000011098 chromatofocusing Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
206010009887 colitis Diseases 0.000 description 1
238000004590 computer program Methods 0.000 description 1
108010005226 connexin 30.3 Proteins 0.000 description 1
108010015417 connexin 36 Proteins 0.000 description 1
108091036078 conserved sequence Proteins 0.000 description 1
238000001816 cooling Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
229920006037 cross link polymer Polymers 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000001804 debridement Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
210000000852 deltoid muscle Anatomy 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000001687 destabilization Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
229940008099 dimethicone Drugs 0.000 description 1
239000004205 dimethyl polysiloxane Substances 0.000 description 1
235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
238000009826 distribution Methods 0.000 description 1
NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
150000002066 eicosanoids Chemical class 0.000 description 1
201000008184 embryoma Diseases 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
239000003344 environmental pollutant Substances 0.000 description 1
210000003560 epithelium corneal Anatomy 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
231100000573 exposure to toxins Toxicity 0.000 description 1
210000003195 fascia Anatomy 0.000 description 1
235000019197 fats Nutrition 0.000 description 1
ZWJINEZUASEZBH-UHFFFAOYSA-N fenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 description 1
230000000893 fibroproliferative effect Effects 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
JLYXXMFPNIAWKQ-GNIYUCBRSA-N gamma-hexachlorocyclohexane Chemical compound Cl[C@H]1[C@H](Cl)[C@@H](Cl)[C@@H](Cl)[C@H](Cl)[C@H]1Cl JLYXXMFPNIAWKQ-GNIYUCBRSA-N 0.000 description 1
JLYXXMFPNIAWKQ-UHFFFAOYSA-N gamma-hexachlorocyclohexane Natural products ClC1C(Cl)C(Cl)C(Cl)C(Cl)C1Cl JLYXXMFPNIAWKQ-UHFFFAOYSA-N 0.000 description 1
229940044627 gamma-interferon Drugs 0.000 description 1
239000007789 gas Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000003349 gelling agent Substances 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
229940045109 genistein Drugs 0.000 description 1
TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
235000006539 genistein Nutrition 0.000 description 1
ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
239000003292 glue Substances 0.000 description 1
229940075529 glyceryl stearate Drugs 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
229960003132 halothane Drugs 0.000 description 1
230000036541 health Effects 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
210000005003 heart tissue Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
239000003906 humectant Substances 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
239000008309 hydrophilic cream Substances 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
208000036260 idiopathic disease Diseases 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000002650 immunosuppressive therapy Methods 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000035990 intercellular signaling Effects 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
208000023589 ischemic disease Diseases 0.000 description 1
235000015110 jellies Nutrition 0.000 description 1
210000000281 joint capsule Anatomy 0.000 description 1
230000008407 joint function Effects 0.000 description 1
235000019388 lanolin Nutrition 0.000 description 1
229940039717 lanolin Drugs 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
210000003041 ligament Anatomy 0.000 description 1
229960002809 lindane Drugs 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000008308 lipophilic cream Substances 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
208000007903 liver failure Diseases 0.000 description 1
231100000835 liver failure Toxicity 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
230000033001 locomotion Effects 0.000 description 1
230000007774 longterm Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
208000002780 macular degeneration Diseases 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000002609 medium Substances 0.000 description 1
229960001962 mefloquine Drugs 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
230000009401 metastasis Effects 0.000 description 1
HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000004200 microcrystalline wax Substances 0.000 description 1
235000019808 microcrystalline wax Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229910000403 monosodium phosphate Inorganic materials 0.000 description 1
235000019799 monosodium phosphate Nutrition 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
WKOVRQFUCLHTHB-UHFFFAOYSA-N n-(ethyliminomethylideneamino)-n-methylmethanamine Chemical compound CCN=C=NN(C)C WKOVRQFUCLHTHB-UHFFFAOYSA-N 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
210000000944 nerve tissue Anatomy 0.000 description 1
210000004498 neuroglial cell Anatomy 0.000 description 1
125000004433 nitrogen atom Chemical group N* 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
QNDVLZJODHBUFM-WFXQOWMNSA-N okadaic acid Chemical compound C([C@H](O1)[C@H](C)/C=C/[C@H]2CC[C@@]3(CC[C@H]4O[C@@H](C([C@@H](O)[C@@H]4O3)=C)[C@@H](O)C[C@H](C)[C@@H]3[C@@H](CC[C@@]4(OCCCC4)O3)C)O2)C(C)=C[C@]21O[C@H](C[C@@](C)(O)C(O)=O)CC[C@H]2O QNDVLZJODHBUFM-WFXQOWMNSA-N 0.000 description 1
VEFJHAYOIAAXEU-UHFFFAOYSA-N okadaic acid Natural products CC(CC(O)C1OC2CCC3(CCC(O3)C=CC(C)C4CC(=CC5(OC(CC(C)(O)C(=O)O)CCC5O)O4)C)OC2C(O)C1C)C6OC7(CCCCO7)CCC6C VEFJHAYOIAAXEU-UHFFFAOYSA-N 0.000 description 1
FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
229940055577 oleyl alcohol Drugs 0.000 description 1
XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
208000005207 oral submucous fibrosis Diseases 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
238000012856 packing Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000002245 particle Substances 0.000 description 1
239000006072 paste Substances 0.000 description 1
230000037361 pathway Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000012466 permeate Substances 0.000 description 1
229940066842 petrolatum Drugs 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
150000004713 phosphodiesters Chemical class 0.000 description 1
150000008298 phosphoramidates Chemical class 0.000 description 1
125000005642 phosphothioate group Chemical group 0.000 description 1
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229960000502 poloxamer Drugs 0.000 description 1
229920001992 poloxamer 407 Polymers 0.000 description 1
229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
239000004633 polyglycolic acid Substances 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920006254 polymer film Polymers 0.000 description 1
235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
235000019422 polyvinyl alcohol Nutrition 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
208000003476 primary myelofibrosis Diseases 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
OLBCVFGFOZPWHH-UHFFFAOYSA-N propofol Chemical compound CC(C)C1=CC=CC(C(C)C)=C1O OLBCVFGFOZPWHH-UHFFFAOYSA-N 0.000 description 1
229960004134 propofol Drugs 0.000 description 1
230000009822 protein phosphorylation Effects 0.000 description 1
238000004080 punching Methods 0.000 description 1
210000003314 quadriceps muscle Anatomy 0.000 description 1
229960001404 quinidine Drugs 0.000 description 1
229960000948 quinine Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
230000006798 recombination Effects 0.000 description 1
238000005215 recombination Methods 0.000 description 1
230000037309 reepithelialization Effects 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
230000010076 replication Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000008458 response to injury Effects 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
229930002330 retinoic acid Natural products 0.000 description 1
210000000574 retroperitoneal space Anatomy 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
210000005241 right ventricle Anatomy 0.000 description 1
210000001991 scapula Anatomy 0.000 description 1
RCTGMCJBQGBLKT-PAMTUDGESA-N scarlet red Chemical compound CC1=CC=CC=C1\N=N\C(C=C1C)=CC=C1\N=N\C1=C(O)C=CC2=CC=CC=C12 RCTGMCJBQGBLKT-PAMTUDGESA-N 0.000 description 1
229960005369 scarlet red Drugs 0.000 description 1
230000037390 scarring Effects 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
206010039722 scoliosis Diseases 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
210000000323 shoulder joint Anatomy 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000000935 solvent evaporation Methods 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000011477 surgical intervention Methods 0.000 description 1
210000001258 synovial membrane Anatomy 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
229960001603 tamoxifen Drugs 0.000 description 1
210000004876 tela submucosa Anatomy 0.000 description 1
210000002435 tendon Anatomy 0.000 description 1
JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
229960003279 thiopental Drugs 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
230000007838 tissue remodeling Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
230000007306 turnover Effects 0.000 description 1
201000001862 viral hepatitis Diseases 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
235000012711 vitamin K3 Nutrition 0.000 description 1
239000011652 vitamin K3 Substances 0.000 description 1
229940046010 vitamin k Drugs 0.000 description 1
229940041603 vitamin k 3 Drugs 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000011240 wet gel Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1
MPDGHEJMBKOTSU-PMTKVOBESA-N β-glycyrrhetinic acid Chemical compound C([C@@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-PMTKVOBESA-N 0.000 description 1